CDTX SEC फाइलिंग - Cidara Therapeutics, Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	549300IHQ9Z7RI1X2D22
CIK	1610618

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cidara Therapeutics, Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

August 7, 2025	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results •Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups •End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA) •Closed upsized public offering for gross
August 7, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-8 Cidara Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended (Common Stock, $0.0001 par value per share
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Cidara Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
August 7, 2025	S-8	As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
June 25, 2025	EX-99.2	Cidara Announces Pricing of Upsized Public Offering of Common Stock EX-99.2 Exhibit 99.2 Cidara Announces Pricing of Upsized Public Offering of Common Stock San Diego, June 24, 2025 - Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price t
June 25, 2025	EX-99.1	Cidara Announces Proposed Public Offering of Common Stock Exhibit 99.1 Cidara Announces Proposed Public Offering of Common Stock San Diego, June 23, 2025 – Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250
June 25, 2025	EX-1.1	Underwriting Agreement, dated June 24, 2025, by and among Cidara Therapeutics, Inc. and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein. Exhibit 1.1 Cidara Therapeutics, Inc. 7,954,546 Shares of Common Stock Underwriting Agreement June 24, 2025 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Guggenheim Securities, LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585
June 25, 2025	424B5	7,954,546 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-287104 Prospectus Supplement (To prospectus dated May 15, 2025) 7,954,546 Shares Common Stock We are offering 7,954,546 shares of our common stock at a purchase price of $44.00 per share. Our common stock is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CDTX.” On June 23, 2025, the last reported sale
June 25, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Cidara Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
June 24, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Cidara Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
June 23, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
June 23, 2025	EX-99.1	NASDAQ: CDTX NAVIGATE Ph 2B June 23, 2025 JUNE 2025 2 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “estimate,” “plan”, ex9912025-06x23 NASDAQ: CDTX NAVIGATE Ph 2B June 23, 2025 JUNE 2025 2 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
June 23, 2025	424B5	SUBJECT TO COMPLETION, DATED JUNE 23, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-287104 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
June 20, 2025	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 20, 2025). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat
June 20, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
June 20, 2025	EX-10.1	Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended, Form of Grant Notice, Stock Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement thereunder Exhibit 10.1 Cidara Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2024 Approved by the Stockholders: July 18, 2024 Amended by the Board of Directors: March 14, 2025 Approved by the Stockholders: June 18, 2025 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of 12:01 a.m. Pacific
May 13, 2025	CORRESP	Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 CORRESP Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: May 8, 2025 File No.
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
May 8, 2025	EX-10.5	, dated May 8, 2025, by and between Cidara Therapeutics, Inc. and Jefferies LLC Exhibit 10.5 OPEN MARKET SALE AGREEMENTSM1 May 8, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common
May 8, 2025	EX-4.9	Form of Indenture, between the Registrant and one or more trustees to be named EX-4.9 Exhibit 4.9 CIDARA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s C
May 8, 2025	EX-4.13	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.13 Exhibit 4.13 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o
May 8, 2025	EX-4.12	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.12 Exhibit 4.12 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] o
May 8, 2025	EX-4.11	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.11 Exhibit 4.11 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized
May 8, 2025	EX-10.4	Employment offer letter between the Registrant and Nicole Davarpanah, M.D., J.D., dated April 25, 2025. Exhibit 10.4 April 25, 2025 [BY EMAIL] Nicole Davarpanah, M.D., J.D. 14403 Marine Drive Silver Spring, MD 20905 Re: Employment Agreement Dear Nicole: This agreement (the “Agreement”) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the “Company”). This Agreement will become effective as of May 1, 2025, upon your acceptance by executing this Agreeme
May 8, 2025	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cidara Therapeutics, Inc.
May 8, 2025	S-3	As filed with the Securities and Exchange Commission on May 8, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cidara Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizatio
May 8, 2025	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results •Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 •Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and
April 25, 2025	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 25, 2025	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 15, 2025	PRE 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 6, 2025	EX-10.30	Employment offer letter between the Registrant and Frank Karbe, dated February 14, 2025. Exhibit 10.30 February 7, 2025 BY EMAIL Frank Karbe Mill Valley, CA Re: Employment Agreement Dear Frank: This agreement (the “Agreement”) sets forth the terms of your employment as the Chief Financial Officer of Cidara Therapeutics, Inc. (the “Company”). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. Upo
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU
March 6, 2025	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results •Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial •Severe flu season enables potential mid-year assessment of efficacy •Closed $105.0 million financing with new and existing investors •Significantly expanded equity research coverage SAN DIEGO, March 6, 2025 — Cida
March 6, 2025	S-8	As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
March 6, 2025	EX-10.5	Non-Employee Director Compensation Policy, as amended. Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 6, 2024 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe
March 6, 2025	EX-10.7	2020 Inducement Incentive Plan, as amended (incorporated by reference to Exhibit 10.7 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 6, 2025). Exhibit 10.7 Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 Amended by the Compensation and Human Capital Committee of the Board of Directors: July 18, 2024 Amended by the Compensation and Human Capital Committee of the Board of Directors: February 12, 2025
March 6, 2025	EX-19.1	Insider Trading Policy of the Registrant. Exhibit 19.1 CIDARA THERAPEUTICS, INC. INSIDER TRADING POLICY PERSONS COVERED This Insider Trading Policy of Cidara Therapeutics, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and its subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live i
March 6, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.
March 6, 2025	EX-4.5	Description of the Registrant’s Securities. Exhibit 4.5 DESCRIPTION OF COMMON STOCK General The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation, inc
February 18, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
February 18, 2025	EX-10.1	Separation Agreement by and between the Registrant and Preetam Shah, dated February 14, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 18, 2025). Exhibit 10.1 February 14, 2025 Preetam Shah, PhD, MBA VIA EMAIL/DOCUSIGN Dear Preetam: This letter sets forth the substance of the separation agreement (the “Agreement”) that Cidara Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be February 24, 2025 (the “Sep
January 7, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
January 7, 2025	EX-99.1	Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2024 Exhibit 99.1 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2024 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe
January 7, 2025	EX-10.1	Separation Agreement by and between the Registrant and Taylor Sandison, dated January 7, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on January 7, 2025). Exhibit 10.1 January 7, 2025 Taylor Sandison 1042 3rd Street, Encinitas, CA 92024 [email protected] VIA EMAIL/DOCUSIGN Dear Taylor: This letter sets forth the substance of the separation agreement (the “Agreement”) that Cidara Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your last day of work with the Company and your employment termination
January 2, 2025	424B3	7,041,309 shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284022 PROSPECTUS 7,041,309 shares of Common Stock This prospectus covers the offer and resale from time to time of up to an aggregate of 7,041,309 shares (the “Resale Shares”) of our common stock, par value $0.0001 per share (the “Common Stock”), of which 3,892,274 are issued and outstanding (the “Shares”) and 3,149,035 share
December 30, 2024	CORRESP	Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 December 30, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 Filed: December 23, 2024 File No. 3
December 23, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cidara Therapeutics, Inc.
December 23, 2024	S-1	As filed with the Securities and Exchange Commission on December 23, 2024 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CIDARA THERAPEUTI Table of Contents As filed with the Securities and Exchange Commission on December 23, 2024 REGISTRATION NO.
December 9, 2024	EX-99.1	Joint Filing Statement EX-99.1 2 ea022411801ex99-1cidara.htm JOINT FILING STATEMENT EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fili
December 9, 2024	SC 13G	CDTX / Cidara Therapeutics, Inc. / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 ea0224118-13gvivocidara.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event which Requires Filing of this Statement)
December 4, 2024	SC 13G	CDTX / Cidara Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment SC 13G 1 tm2430061d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement) Che
December 3, 2024	SC 13G	CDTX / Cidara Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d837379dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of This Statement) Check
December 3, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d837379dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that
November 26, 2024	EX-10.2	Registration Rights Agreement, by and among the Registrant and the persons party thereto, dated November 20, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 20, 2024, is entered into by and among Cidara Therapeutics Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms
November 26, 2024	EX-10.1	Securities Purchase Agreement, by and among the Registrant and the purchasers named therein, dated November 20, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 20, 2024, by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver
November 26, 2024	EX-4.1	Form of Pre-Funded Warrant to Purchase Common Stock for Private Placement (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024). Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN
November 26, 2024	EX-99.1	Cidara Therapeutics Announces $105 Million Private Placement Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors Exhibit 99.1 Cidara Therapeutics Announces $105 Million Private Placement Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors SAN DIEGO, November 21, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)
November 26, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
November 26, 2024	SC 13D/A	CDTX / Cidara Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2429639d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, M
November 26, 2024	EX-1	Joint Filing Agreement EX-1 2 tm2429639d1ex1.htm EXHIBIT 1 CUSIP No. 171757206 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 26, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Sec
November 14, 2024	SC 13G/A	CDTX / Cidara Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 6 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga607422cdtx11142024.htm AMENDMENT NO. 6 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value
November 7, 2024	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results SAN DIEGO, November 7, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious dise
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
September 23, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga
September 12, 2024	8-K	Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
August 13, 2024	S-8	As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration No.
August 13, 2024	EX-10.3	2020 Inducement Plan of the Registrant, as amended. Exhibit 10.3 Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 Amended by the Compensation and Human Capital Committee of the Board of Directors: July 18, 2024 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under
August 13, 2024	EX-10.4	License and Technology Agreement, by and between the Registrant and Janssen Pharmaceuticals, Inc., dated April 23, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 13, 2024). Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version LICENSE AND TECHNOLOGY TRANSFER AGREEMENT between CIDARA THERAPEUTICS, INC. and JANSSEN PHARMACEUTICALS, INC. April 23, 2024 TABLE OF CONTENTS Page 1.
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
August 13, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.
August 13, 2024	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results SAN DIEGO, August 13, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious dise
August 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
July 31, 2024	424B3	16,800,000 shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280919 PROSPECTUS 16,800,000 shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 16,800,000 shares of our common stock. An aggregate of 240,000 shares of our Series A Convertible Voting Preferred Stock, par value $0.0001 per share
July 29, 2024	CORRESP	Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 July 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 Filed: July 19, 2024 File No. 333-280919 Ladies a
July 29, 2024	EX-99.1	Joint Filing Agreement EX-99.1 3 d856817dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders
July 29, 2024	SC 13G	CDTX / Cidara Therapeutics, Inc. / BCLS Fund III Investments, LP - SC 13G Passive Investment SC 13G 1 d868204dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par
July 29, 2024	EX-24	POWER OF ATTORNEY EX-24 2 d856817dex24.htm EX-24 Exhibit 24 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signatu
July 29, 2024	SC 13G	CDTX / Cidara Therapeutics, Inc. / Canaan XII L.P. - SC 13G Passive Investment SC 13G 1 d856817dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CIDARA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 171757 20 6 (CUSIP Number) July 18, 2024 (Date of Event Which Requires Filing of this Statement) Check th
July 25, 2024	SC 13D	CDTX / Cidara Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment SC 13D 1 tm2420136d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116
July 19, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cidara Therapeutics, Inc.
July 19, 2024	S-1	Power of Attorney. Reference is made to the signature page hereto. S-1 Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 REGISTRATION NO.
July 18, 2024	EX-10.1	2024 Equity Incentive Plan of the Registrant, Form of Grant Notice, Stock Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement Thereunder. Exhibit 10.1 Cidara Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2024 Approved by the Stockholders: July 18, 2024 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of 12:01 a.m. Pacific Standard Time on the Effective Date, (i) no additional awards may be granted under the Prior
July 18, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
July 18, 2024	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on July 18, 2024). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat
June 3, 2024	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 3, 2024	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 23, 2024	PRE 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Cidara Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati
May 15, 2024	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results SAN DIEGO, May 15, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
May 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati
May 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Cidara Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizatio
May 3, 2024	EX-99.1	1 Corporate Presentation: May 2024 NASDAQ: CDTX 2 Fo r w a rd - L o o k i n g S ta t e m e n t s T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i corporatepresentation202 1 Corporate Presentation: May 2024 NASDAQ: CDTX 2 Fo r w a rd - L o o k i n g S ta t e m e n t s T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .
April 29, 2024	EX-2.3	First Amendment to Melinta License Agreement, dated April 23, 2024, by and between Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. Exhibit 2.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment to the License Agreement (“Amendment”) is entered into and effective as of April 23, 2024 (the “Amendment Date”)
April 29, 2024	EX-2.2	Assignment and Novation Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited. Exhibit 2.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Assignment and Novation Agreement This Assignment and Novation agreement (“Agreement”) dated as of April 24, 2024 (the “Effective Date”), is entered into by and among CID
April 29, 2024	EX-2.1	Asset Purchase Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited. Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT BY AND BETWEEN CIDARA THERAPEUTICS, INC. AND NAPP PHARMACEUTICAL GROUP LIMITED DATED AS OF 24 APRIL, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINI
April 29, 2024	8-K/A	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorpo
April 24, 2024	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 24, 2024). Exhibit 3.1 EXECUTION VERSION CIDARA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “D
April 24, 2024	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
April 24, 2024	EX-10.1	Securities Purchase Agreement, by and among Cidara Therapeutics, Inc. and the purchasers named therein. Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 23, 2024, by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS
April 24, 2024	EX-10.2	Form of Support Agreement. Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of April 23, 2024, is made by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”) and the other persons and entities set forth on the signature pages hereto (the “Stockholders”). The Company and the Stockholders shall be referred to herein from time to time collectively as the “Parties.” Capi
April 24, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
April 23, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.
April 23, 2024	S-8	As filed with the Securities and Exchange Commission on April 22, 2024 As filed with the Securities and Exchange Commission on April 22, 2024 Registration No.
April 22, 2024	EX-97.1	Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy. Exhibit 97.1 Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy adopted December 1, 2023 1.Introduction The Board of Directors (the “Board”) of Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the
April 22, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
April 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU
April 22, 2024	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April 22, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing
April 22, 2024	EX-10.5	Non-Employee Director Compensation Policy, as amended (incorporated by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K, filed on April 22, 2024). Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 4, 2023 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe
April 22, 2024	EX-99.2	Cidara Therapeutics Announces Reverse Stock Split Exhibit 99.2 Cidara Therapeutics Announces Reverse Stock Split SAN DIEGO, April 22, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected
April 22, 2024	EX-3.2	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on April 22, 2024). Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat
April 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Cidara Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
April 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Cidara Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
April 1, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36912 CUSIP NUMBER NOTIFICATION OF LATE FILING 171757107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36912 CUSIP NUMBER NOTIFICATION OF LATE FILING 171757107 (Check one): ý Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra
March 4, 2024	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 23, 2024	PRE 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	CDTX / Cidara Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 5 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga507422cdtx02142024.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value
February 14, 2024	SC 13G/A	CDTX / Cidara Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
February 14, 2024	SC 13G/A	CDTX / Cidara Therapeutics, Inc. / Point72 Asset Management, L.P. - CIDARA THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Cidara Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Cidara Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Cidara Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
November 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Cidara Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
November 2, 2023	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, November 2, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
November 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
October 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Cidara Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
October 13, 2023	EX-99.1	Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1 Exhibit 99.1 Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1 •The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 •If approved by the European Medicines Agency, rezafungin
September 21, 2023	EX-99.1	R&D Day SEPTEMBER 21, 2023 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words R&D Day SEPTEMBER 21, 2023 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .
September 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Cidara Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga
September 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Cidara Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
September 6, 2023	EX-99.1	Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to Exhibit 99.1 Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties SAN DIEGO, Sep
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cidara Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
August 3, 2023	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results SAN DIEGO, August 3, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2023 and pro
July 7, 2023	CORRESP	July 7, 2023 July 7, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Cidara Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
May 31, 2023	CORRESP	Year Ended December 31, 2021 (in thousands) Mundipharma Janssen Melinta Revenue from Collaboration and License Agreements: Point in Time: License of Intellectual Property – upon transfer of license $ — $ 27,000 $ — License of Intellectual Property – May 31, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cidara Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati
May 11, 2023	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results SAN DIEGO, May 11, 2023 — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31,
May 11, 2023	EX-10.1	Seventh Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated April 20, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 11, 2023). Exhibit 10.1 SEVENTH AMENDMENT TO LEASE DATED APRIL 20, 2023 Nancy Ridge Technology Center, L.P., a California limited partnership (“Lessor”), and Cidara Therapeutics, Inc., a Delaware corporation, (“Lessee”), hereby amend the Lease dated June 9, 2014 (as previously amended, the “Lease”), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 (“Premises”) as follows: 1)Expirat
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
April 27, 2023	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 27, 2023	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 23, 2023	S-8	As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.
March 23, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.
March 23, 2023	EX-10.5	Non-Employee Director Compensation Policy, as amended. Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2022 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe
March 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU
March 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Cidara Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
March 23, 2023	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN DIEGO, March 23, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full
March 6, 2023	EX-1.2	Underwriting Agreement, dated March 3, 2023, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Series X Convertible Preferred Stock) EX-1.2 Exhibit 1.2 286,000 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENT March 3, 2023 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell t
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Cidara Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
March 6, 2023	424B5	9,640,000 Shares Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 PROSPECTUS SUPPLEMENT (To Prospectus dated November 22, 2021) 9,640,000 Shares Common Stock We are offering 9,640,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “CDTX.” On March 3, 2023, the last reported sale price of our common stock on the Nasdaq Capital
March 6, 2023	EX-1.1	Underwriting Agreement, dated March 3, 2023, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Common Stock). EX-1.1 Exhibit 1.1 9,640,000 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENT March 3, 2023 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwrit
March 6, 2023	424B5	286,000 Shares Series X Convertible Preferred Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 PROSPECTUS SUPPLEMENT (To Prospectus dated November 22, 2021) 286,000 Shares Series X Convertible Preferred Stock We are offering 286,000 shares of our Series X convertible preferred stock, or the Series X Preferred Stock (and the common stock issuable from time to time upon conversion of the Series X Preferred St
March 2, 2023	424B5	SUBJECT TO COMPLETION, DATED MARCH 2, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
March 2, 2023	424B5	SUBJECT TO COMPLETION, DATED MARCH 2, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Cidara Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Cidara Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
February 14, 2023	EX-99.1	1 Exhibit 99.1 Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, February 14, 2023 – Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq Stock Market, LLC (“Na
February 14, 2023	SC 13G/A	CDTX / Cidara Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236168d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen
February 14, 2023	SC 13G/A	CDTX / Cidara Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Cidara Therapeutics, Inc. (Title of Class of Securities) Common Stock, par value $0.0
February 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cidara Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Cidara Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
November 29, 2022	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 10, 2022	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 3, 2022	EX-10.4	Employment offer letter between the Registrant and Preetam Shah, dated August 19, 2021 (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022). Exhibit 10.4 August 19, 2021 BY EMAIL Re: Employment Agreement Dear Preetam: This agreement (the ?Agreement?) sets forth the terms of your employment as the Chief Financial Officer and Chief Business Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. As t
November 3, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Cidara Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
November 3, 2022	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results SAN DIEGO, November 3, 2022 — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2
November 3, 2022	EX-10.2	Employment offer letter between the Registrant and Taylor Sandison, dated March 22, 2017 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022). Exhibit 10.2 March 22, 2017 BY HAND DELIVERY AND EMAIL Taylor Sandison Re: Employment Agreement Dear Taylor: This letter (the ?Agreement?) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to Allison Lewis. As of
November 3, 2022	EX-10.1	License Agreement by and between the Registrant and Melinta Therapeutics, LLC, dated July 26, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) dated as of July 26, 2022 (the ?Effective Date?), is entered into between Cidara Therapeutics, Inc., a Delaware corporatio
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
November 3, 2022	EX-10.3	Employment offer letter between the Registrant and Shane M. Ward, dated August 17, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022). Exhibit 10.3 August 17, 2021 BY EMAIL Re: Employment Agreement Dear Shane: This agreement (the ?Agreement?) sets forth the terms of your continued employment as the Chief Legal Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. Upon commencement of your e
October 31, 2022	PRE 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
October 21, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Cidara Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi
September 8, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
September 2, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
August 9, 2022	EX-10.2	Letter Agreement by and between the Registrant and Mundipharma Medical Company, dated April 20, 2022 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 9, 2022). Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[***]?. This Third Letter Agreement (?Third Letter Agreement?) is made by and between Cidara Therapeutic
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
August 9, 2022	EX-10.1	Fifth Amendment to Loan and Security Agreement by and between the Registrant and Pacific Western Bank, dated April 4, 2022. Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is made and entered into as of April 4, 2022, by and between PACIFIC WESTERN BANK, a California state chartered bank (?Bank?), and CIDARA THERAPEUTICS, INC. (?Borrower?). RECITALS Borrower and Bank are parties to that certain Loan and Security Agreement dated as of Oct
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
August 9, 2022	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results SAN DIEGO, August 9, 2022 ? Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and pr
July 27, 2022	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
July 7, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati
July 7, 2022	EX-99.1	1 D F C s : a n e w c l a s s o f d r u g s b r e a k i n g g r o u n d i n a n t i - v i r a l s a n d o n c o l o g y J u l y 7 , 2 0 2 2 2 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e 1 D F C s : a n e w c l a s s o f d r u g s b r e a k i n g g r o u n d i n a n t i - v i r a l s a n d o n c o l o g y J u l y 7 , 2 0 2 2 2 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .
June 24, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
May 11, 2022	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results SAN DIEGO, May 11, 2022 ? Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provi
May 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati
April 29, 2022	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 29, 2022	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza
March 7, 2022	EX-10.26	Fifth Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated January 13, 2020 (incorporated by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K, filed on March 7, 2022). Exhibit 10.26 FIFTH AMENDMENT TO LEASE DATED JANUARY 13, 2020 Nancy Ridge Technology Center, L.P., a California limited partnership ("Lessor"), and Cidara Therapeutics, Inc., a Delaware corporation, ("Lessee"), hereby amend the Lease dated June 9, 2014 (as previously amended, the "Lease"), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 ("Premises") as follows: 1)Genera
March 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat
March 7, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.
March 7, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU
March 7, 2022	EX-10.5	Non-Employee Director Compensation Policy, as amended. Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 13, 2021 Each member of the Cidara Therapeutics, Inc. Board of Directors (the ?Board?) who is not also serving as an employee of Cidara Therapeutics, Inc. (?Cidara?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the comp
March 7, 2022	EX-99.1	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results SAN DIEGO, March 7, 2022 ? Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year e
March 7, 2022	S-8	As filed with the Securities and Exchange Commission on March 7, 2022 As filed with the Securities and Exchange Commission on March 7, 2022 Registration No.
March 4, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
February 15, 2022	SC 13G/A	CDTX / Cidara Therapeutics Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
February 14, 2022	EX-99.2	POWER OF ATTORNEY CUSIP NO. 171757107 13G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person?s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the ?Reports?),
February 14, 2022	SC 13G/A	CDTX / Cidara Therapeutics Inc / Omega Fund V, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 3)* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2021 (Date of Event Which Req
February 14, 2022	EX-99.1	AGREEMENT CUSIP No. 171757107 13 G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Cidara Therapeutics, Inc. Dated: February 14, 2022 OMEGA FUND V, L.P. BY:
February 14, 2022	SC 13G/A	CDTX / Cidara Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Cidara Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
February 14, 2022	SC 13G	CDTX / Cidara Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t
February 11, 2022	SC 13G/A	CDTX / Cidara Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this
December 16, 2021	SC 13G/A	CDTX / Cidara Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 4 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 171757107 (CUSIP Numbe
December 14, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
December 14, 2021	EX-99.1	Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Trial met FDA and EMA-pre-specified primary endpoints versus da Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.
December 14, 2021	EX-99.2	1 ReSTORE PHASE 3 TRIAL RESULTS FOR REZAFUNGIN L E A D I N G T H E S C I E N C E O F P R O T E C T I O N D e c 2 0 2 1 2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t 1 ReSTORE PHASE 3 TRIAL RESULTS FOR REZAFUNGIN L E A D I N G T H E S C I E N C E O F P R O T E C T I O N D e c 2 0 2 1 2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .
November 18, 2021	CORRESP	Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 November 18, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Cidara Therapeutics, Inc. (the ?Company?) Registration Statement on Form S-3 Filed: November 10, 2021 File No. 333-260970 Ladies and Gentlem
November 10, 2021	EX-4.6	Form of Debt Indenture. EXHIBIT 4.6 CIDARA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 S
November 10, 2021	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results SAN DIEGO, November 10, 2021 ? Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2021 and provided
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
November 10, 2021	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.9 CIDARA THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 CIDARA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between CIDARA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organized
November 10, 2021	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.8 CIDARA THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 CIDARA THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between CIDARA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organized and exist
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
November 10, 2021	S-3	As filed with the Securities and Exchange Commission on November 10, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2021 Registration No.
November 10, 2021	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. EXHIBIT 4.10 CIDARA THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 CIDARA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of between CIDARA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organized
October 14, 2021	SC 13G	CDTX / Cidara Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Cidara Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.00
October 14, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
October 8, 2021	424B5	774,194 Shares Series X Convertible Preferred Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228268 PROSPECTUS SUPPLEMENT (To Prospectus dated November 15, 2018) 774,194 Shares Series X Convertible Preferred Stock We are offering 774,194 shares of our Series X convertible preferred stock, or the Series X Preferred Stock (and our common stock issuable from time to time upon the conversion of the Series X Preferred Stoc
October 8, 2021	EX-1.1	Underwriting Agreement, dated October 7, 2021, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Common Stock) Exhibit 1.1 14,838,706 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENT October 7, 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several underwriters
October 8, 2021	EX-1.2	Underwriting Agreement, dated October 7, 2021, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Series X Convertible Preferred Stock) Exhibit 1.2 774,194 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENT October 7, 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the
October 8, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
October 8, 2021	EX-99.1	CIDARA THERAPEUTICS ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND PREFERRED STOCK Exhibit 99.1 CIDARA THERAPEUTICS ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND PREFERRED STOCK SAN DIEGO, October 8, 2021 (GLOBE NEWSWIRE) ? Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate
October 8, 2021	424B5	14,838,706 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-228268 PROSPECTUS SUPPLEMENT (To Prospectus dated November 15, 2018) 14,838,706 Shares Common Stock We are offering 14,838,706 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol ?CDTX.? On October 6, 2021, the last reported sale price of our common stock wa
October 7, 2021	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 7, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228268 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
October 7, 2021	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 7, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-228268 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
September 21, 2021	EX-99.1	1 C I D A R A R & D D AY S E P T 2 1 s t 2 0 2 1 2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i 1 C I D A R A R & D D AY S E P T 2 1 s t 2 0 2 1 2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .
September 21, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga
September 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ
August 31, 2021	S-8	As filed with the Securities and Exchange Commission on August 31, 2021 As filed with the Securities and Exchange Commission on August 31, 2021 Registration No.
August 31, 2021	EX-99.1	Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8, filed on August 31, 2021). Exhibit 99.1 Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketpla
August 17, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
August 17, 2021	EX-99.1	Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for Exhibit 99.1 Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, August 17, 2021 (GLOBE NEWSWIRE) ? Cidara Therapeutics, Inc. (Nasdaq: CDTX) a
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.
August 12, 2021	EX-99.A	JOINT FILING STATEMENT EX-99.A Exhibit A JOINT FILING STATEMENT I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Cidara Therapeutics, Inc. is filed on behalf of each of the undersigned. Date: August 11, 2021 INTERWEST PARTNERS X, L.P. By: InterWest Management Partners X, LLC Its: General Partner By: /s/ Karen A. Wilson KAREN A. WI
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz
August 12, 2021	EX-99.1	CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) Exhibit 99.1 Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results SAN DIEGO, August 12, 2021 (GLOBE NEWSWIRE) ? Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter e
August 12, 2021	EX-10.3	Sixth Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated July 14, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 12, 2021). Exhibit 10.3 SIXTH AMENDMENT TO LEASE Nancy Ridge Technology Center, L.P., a California limited partnership (?Lessor?), and Cidara Therapeutics, Inc., a Delaware corporation, (?Lessee?), hereby amend the Lease dated June 9, 2014 (as previously amended, the ?Lease?), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 (?Premises?) effective as of the date of the last signatu
August 12, 2021	SC 13D/A	CDTX / Cidara Therapeutics Inc / INTERWEST PARTNERS X LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
August 12, 2021	EX-10.2	Form of Amended and Restated Employment Agreement by and between the Registrant and its executive officers (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 12, 2021). Exhibit 10.2 , [DATE] BY EMAIL [see Schedule I: ?Executive Officer?] 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121 Re: Amended & Restated Employment Agreement1 Dear [see Schedule I: ?Executive Officer?]: This employment agreement (the ?Agreement?) sets forth the terms of your continued employment as the [see Schedule I: ?Position?] of Cidara Therapeutics, Inc. (the ?Company?). This Agreeme
July 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

CDTX / Cidara Therapeutics, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)

Other Listings